Twist Bioscience Corporation (TWST)

NASDAQ: TWST · Real-Time Price · USD
32.30
-0.51 (-1.55%)
At close: Dec 5, 2025, 4:00 PM EST
32.94
+0.64 (1.98%)
After-hours: Dec 5, 2025, 6:51 PM EST
-1.55%
Market Cap 1.98B
Revenue (ttm) 376.57M
Net Income (ttm) -77.67M
Shares Out 61.15M
EPS (ttm) -1.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,007,512
Open 32.63
Previous Close 32.81
Day's Range 31.85 - 32.80
52-Week Range 23.30 - 55.33
Beta 2.24
Analysts Buy
Price Target 46.33 (+43.44%)
Earnings Date Nov 14, 2025

About TWST

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and ... [Read more]

Sector Healthcare
IPO Date Oct 31, 2018
Employees 979
Stock Exchange NASDAQ
Ticker Symbol TWST
Full Company Profile

Financial Performance

In 2025, Twist Bioscience's revenue was $376.57 million, an increase of 20.32% compared to the previous year's $312.97 million. Losses were -$77.67 million, -62.79% less than in 2024.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for TWST stock is "Buy." The 12-month stock price target is $46.33, which is an increase of 43.44% from the latest price.

Price Target
$46.33
(43.44% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Twist Bioscience Launches New Plasmid Preps to Enable Nucleic Acid Therapeutics Research

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched research-grade Plasmid DNA Preps designed to suppo...

1 day ago - Business Wire

Twist Bioscience Is Bent, Not Broken: Near-Term Strain, Long-Term Strength

Twist's revenue growth continues to moderate due to macro headwinds and temporary challenges in the NGS business. The Biopharma segment is reaccelerating, though, driven by AI-enabled drug discovery c...

17 days ago - Seeking Alpha

Can Twist Bioscience Drop More?

Twist Bioscience (TWST) stock has decreased by 10.1% in one day. The recent downturn signifies renewed worries regarding wider-than-anticipated losses and ambiguous profitability guidance, but signifi...

18 days ago - Forbes

Twist Bioscience Corporation (TWST) Q4 2025 Earnings Call Transcript

Twist Bioscience Corporation (TWST) Q4 2025 Earnings Call Transcript

21 days ago - Seeking Alpha

Twist Bioscience Eyes Profit Turnaround In 2026 After Narrowing Losses

Twist Bioscience Corporation (NASDAQ: TWST) on Friday posted mixed fourth-quarter results, reporting a loss of 45 cents per share, slightly wider than the consensus estimate of a 43-cent loss.

21 days ago - Benzinga

Twist Bioscience Announces Fiscal 2025 Fourth Quarter and Full Year Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced financial results and business highlights for the...

21 days ago - Business Wire

Top Wall Street Forecasters Revamp Twist Bioscience Expectations Ahead Of Q4 Earnings

Twist Bioscience Corporation (NASDAQ: TWST) will release fourth-quarter earnings before the opening bell on Friday, Nov. 14.

21 days ago - Benzinga

Twist Bioscience to Present at 7th Annual Wolfe Research Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder...

4 weeks ago - Business Wire

Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value bi...

4 weeks ago - Business Wire

Halper Sadeh LLC Encourages Twist Bioscience Corporation Shareholders to Contact the Firm to Discuss Their Rights

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Twist Bioscience Corporation (NASDAQ: TWST) breached their fiduciar...

6 weeks ago - Business Wire

Twist Bioscience to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results on Friday, November 14, 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the ...

6 weeks ago - Business Wire

Twist Bioscience and Element Biosciences Advance Collaboration with Launch of New Trinity Freestyle™ Sequencing Workflow for the AVITI™ System

SOUTH SAN FRANCISCO, Calif. & SAN DIEGO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, and Element Biosciences, Inc., a company democratizin...

2 months ago - Business Wire

Twist Bioscience Announces Publication in Science Examining Biosecurity Screening Practices in AI-assisted Protein Design

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced the publication in Science of the peer-reviewed p...

2 months ago - Business Wire

Twist Bioscience to Present at Baird 2025 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder...

3 months ago - Business Wire

Twist Bioscience Collaborates with Synthetic Design Lab

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has collaborated with next generation the...

3 months ago - Business Wire

mRNA Biotechs - Long-Term Value Risks Abound

mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...

3 months ago - Seeking Alpha

Twist Bioscience Launches Oncology DNA CGP Panel to Advance Precision Medicine with Customizable, Platform-Agnostic NGS Solution

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity, in the life sciences segment of the health care sector, today launche...

3 months ago - Business Wire

Twist Bioscience: Headwinds Are Mounting

Twist Bioscience's growth continues to moderate, in part due to macro headwinds. While Twist's focus on transitioning to profitability in the near-term has significantly reduced cash burn, it has also...

4 months ago - Seeking Alpha

Twist Bioscience Appoints Trynka Shineman Blake to Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth equity, today announced the appointment of Trynka Shineman Blake to its board of direct...

4 months ago - Business Wire

Twist Bioscience Turns The Tide: Q3 Sales Jump, Beats Earnings

What if a biotech company could flip its financial narrative from loss to profit in just a year? Twist Bioscience Corporation TWST has done just that, reporting a surprising third-quarter income that ...

4 months ago - Benzinga

Twist Bioscience Corporation (TWST) Q3 2025 Earnings Call Transcript

Twist Bioscience Corporation (NASDAQ:TWST) Q3 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Adam Laponis - Chief Financial Officer Angela Bitting - Chief Corporate Resp...

4 months ago - Seeking Alpha

Twist Bioscience (TWST) Q3 Profit Surges

Twist Bioscience (TWST) Q3 Profit Surges

4 months ago - The Motley Fool

Twist Bioscience Announces Fiscal 2025 Third Quarter Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth equity, today announced financial results and business highlights for the third quarter...

4 months ago - Business Wire

Twist Bioscience Expands In Vivo Antibody Discovery Services with Launch of Humanized Transgenic Mouse Model

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today ...

4 months ago - Business Wire

Twist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a core mid-cap growth and val...

4 months ago - Business Wire